血清滑膜组织转化生物标志物C1M可预测早期类风湿关节炎的影像学进展
基于前瞻性ESPOIR研究813例早期关节炎患者(82%为类风湿关节炎,18%为未分化关节炎),随访5年,评估基线血清C1M和C2M与van der Heijde Sharp评分进展的关联。基线C1M最高四分位组较最低四分位组1年总关节损伤进展的OR为2.75(95%CI 1.70-4.45),校正DAS28、CRP和抗CCP2抗体后OR为2.12(95%CI 1.06-4.23);5年时C1M仍与进展显著相关;C2M与1年或5年进展无显著关联。
要点
- 基线血清C1M最高四分位组1年总关节损伤进展风险是最低四分位组的2.75倍(OR 2.75,95%CI 1.70-4.45)。
- 校正DAS28、CRP和抗CCP2抗体后,高C1M仍与1年进展显著相关(OR 2.12,95%CI 1.06-4.23)。
- C2M与1年或5年影像学进展均无显著关联。
核心结论
- 高基线血清C1M而非C2M与早期关节炎影像学进展增加相关,且独立于经典危险因素。
- C1M结合其他危险因素可能有助于识别关节损伤风险较高的患者。
研究设计与样本
- 前瞻性ESPOIR研究纳入813例早期关节炎患者(症状<6个月,82%为类风湿关节炎,18%为未分化关节炎),随访5年。
- 采用van der Heijde Sharp评分评估影像学进展,进展定义为基线至1年或5年增加1或5个单位。
- 采用逻辑回归评估基线C1M和C2M与进展的关联。
主要发现
- 校正年龄、性别和BMI后,基线连续血清C1M水平升高与1年进展风险相关。
- C1M最高四分位组较低四分位组1年总关节损伤进展的OR为2.75(95%CI 1.70-4.45)。
- 模型中纳入DAS28、CRP和抗CCP2抗体阳性后,高C1M仍与进展显著相关,OR为2.12(95%CI 1.06-4.23)。
- 5年时,校正年龄、性别和BMI后C1M与总关节损伤进展风险显著相关。
- C2M与1年或5年进展无显著关联。
临床怎么用
- 作者认为C1M结合其他危险因素可能有助于识别关节损伤风险较高的患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate whether serum C1M and C2M, biochemical markers of synovial and cartilage tissue destruction, were associated with progression of joint damage in patients with early arthritis. METHODS: 813 early arthritis patients (<6 months of symptoms, 82% with rheumatoid arthritis, 18% undifferentiated arthritis) from the prospective ESPOIR study were followed for 5 years. Radiographic progression was assessed using the van der Heijde Sharp score, and progression was defined as an increase of 1 or 5 unit(s) between baseline and 1 year or 5 years. Associations between baseline C1M and C2M and progression were assessed by logistic regression. RESULTS: Increased baseline continuous serum C1M levels were associated with the risk of progression at 1 year, after adjustment for age, gender and body mass index (BMI). Patients with levels in the highest quartile of C1M had an OR (95% CI) of total joint damage progression of 2.75 (1.70-4.45) compared with patients in the lowest quartile. When disease activity score 28, C reactive protein and anticyclic citrullinated peptide 2 antibodies positivity were included in the model, high C1M remained significantly associated with progression with an OR (95% CI) of 2.12 (1.06-4.23). At 5 years, C1M was significantly associated with the risk of total joint damage progression after adjustment for age, gender and BMI. There was no significant association of C2M with progression at 1 year or 5 years. CONCLUSIONS: High baseline serum C1M, but not C2M, is associated with increased radiographic progression in early arthritis, independently of classical risk factors. C1M, in conjunction with other risk factors, may help identify patients at higher risk of joint damage.
引用
- Garnero P, Falkenløve Madsen S, Eymard F, et al. Serum biochemical marker of synovial tissue turnover, C1M, predicts radiological progression in early rheumatoid arthritis. RMD Open. 2025. PMID: 40639877. doi:10.1136/rmdopen-2025-005501
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。